Posted in Collaborations, Orthopaedics / Rheumatology
FARAN S.A. and STADA Arzneimittel AG, are pleased to announce the beginning of their cooperation in the field of Osteoporosis.
More specifically, in the context of the cooperation with STADA Arzneimittel AG, FARAN undertakes the promotion and distribution in Greek market of Movymia, STADA’s first first bio-similar Teriparatide.
Movymia is indicated for the treatment of Osteoporosis in postmenopausal women and men at increased risk of fracture.
The collaboration will strengthen FARAN’s leading position in the field of biotechnology among Greek companies, as STADA Arzneimittel AG is a world leader in the research, development and production of biosimilars.
As such, FARAN remains faithful to its vision and values, continuing to expand its cooperation with leading pharmaceutical companies, implementing its commitment to the Greek patient and the health system, offering renowned therapeutic proposals of high quality & therapeutic value for the treatment of serious diseases.